Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 18:339:b2942.
doi: 10.1136/bmj.b2942.

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

David N Juurlink  1 , Tara Gomes, Lorraine L Lipscombe, Peter C Austin, Janet E Hux, Muhammad M Mamdani
Affiliations

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

David N Juurlink et al. BMJ. .

Abstract

Objective: To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone.

Design: Retrospective cohort study.

Setting: Ontario, Canada.

Participants: Outpatients aged 66 years and older who were started on rosiglitazone or pioglitazone between 1 April 2002 and 31 March 2008.

Main outcome measure: Composite of death or hospital admission for either acute myocardial infarction or heart failure. In a secondary analysis, each outcome was also examined individually.

Results: 39 736 patients who started on either pioglitazone or rosiglitazone were identified. During the six year study period, the composite outcome was reached in 895 (5.3%) of patients taking pioglitazone and 1563 (6.9%) of patients taking rosiglitazone. After extensive adjustment for demographic and clinical factors and drug doses, pioglitazone treated patients had a lower risk of developing the primary outcome than did patients treated with rosiglitazone (adjusted hazard ratio 0.83, 95% confidence interval 0.76 to 0.90). Secondary analyses revealed a lower risk of death (adjusted hazard ratio 0.86, 0.75 to 0.98) and heart failure (0.77, 0.69 to 0.87) with pioglitazone but no significant difference in the risk of acute myocardial infarction (0.95, 0.81 to 1.11). One additional composite outcome would be predicted to occur annually for every 93 patients treated with rosiglitazone rather than pioglitazone.

Conclusions: Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

None
Fig 1 Survival curves for primary outcome (composite of death or hospital admission for acute myocardial infarction or heart failure) from start of treatment with pioglitazone or rosiglitazone, adjusted for factors outlined in web appendix
None
Fig 2 Survival curves for hospital admission for heart failure from start of treatment with pioglitazone or rosiglitazone, adjusted for factors outlined in web appendix
None
Fig 3 Survival curves for hospital admission for acute myocardial infarction from start of treatment with pioglitazone or rosiglitazone, adjusted for factors outlined in web appendix
None
Fig 4 Survival curves for death from any cause from start of treatment with pioglitazone or rosiglitazone, adjusted for factors outlined in web appendix
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. - PubMed
    1. Haffner SM, D’Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care 1999;22:562-8. - PubMed
    1. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009;131:298-304. - PubMed
    1. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78:1088-91. - PubMed
    1. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6. - PubMed

Publication types